GLİOBLASTOMA İLE ORGANOİDLERİN TERAPÖTİK İLİŞKİLERİNE İN VİTRO YAKLAŞIMLAR
Keywords:
glioblastoma, organoid, 3D hücre kültürüAbstract
Glioblastoma (GBM), en yaygın kötü huylu primer beyin tümörüdür. Glioblastoma’nın cerrahi, radyoterapi, kemoterapi ve hedefe yönelik tedavi tekniklerinde olumlu gelişmeler olsa da prognozu kötü kalmakta ve hayatta kalma çok az orandadır. Glioblastoma, kan-beyin bariyeri boyunca yetersiz ilaç dağıtımı, bol miktarda intratümöral ve intertümöral heterojenlik, gereksiz sinyal yolları ve immünosüpresif bir mikroçevre içermesi nedeniyle tedavisi zordur. Kanser hastalarına bağışıklık güçlendirici tedavi uygulanmasına rağmen bazı durumlarda iyileşme elde edilememekte ve bu durum cerrahi müdahale gerektirmekte veya alternatif hücre tiplerini hedefleyen terapötik yaklaşımlara ihtiyaç duyulmaktadır. Tasarlanmış kanser organoid modelleri; terapötiklerin gelecekte klinik öncesi gelişimi için faydalı olacağı düşünülmektedir. Ayrıca organoidler, GBM hastaları için anti-tümör ilaçları ve kişiselleştirilmiş tıbbın geliştirilmesinde kullanılmaktadır. 3D hücre kültürü modelleme teknikleri ve özel görüntüleme yöntemleri gibi yenilikçi teknolojileri birleştirerek, gerçeğe daha yakın bir beyin tümörü organoid modeli, gelecekte anti-kanser araştırmalarının daha anlaşır olmasına katkı sunacaktır. Bu derlemede 3D organoid modellerin; Glioblastoma’nın moleküler yapısının anlaşılmasına ve farklı tedavi yaklaşımlarına nasıl bir katkı sunduğu araştırılmıştır.
References
[1] Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., and Khasraw, M. (2020): Management of glioblastoma: State of the art and future directions. CA. Cancer J. Clin., vol. 70, no. 4, pp. 299–312.
[2] Taphoorn, M. J. B., Sizoo, E. M., and Bottomley, A. (2010): Review on Quality of Life Issues in Patients with Primary Brain Tumors. Oncologist, vol. 15, no. 6, pp. 618–626.
[3] Ohgaki, H. and Kleihues, P. (2005): Population-Based Studies on Incidence, Survival Rates, and Genetic Alterations in Astrocytic and Oligodendroglial Gliomas. J. Neuropathol. Exp. Neurol., vol. 64, no. 6, pp. 479–489.
[4] Ostrom, Q. T., et al. (2016): CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013. Neuro. Oncol., vol. 18, no. suppl_5, pp. v1–v75.
[5] Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., and Neamati, N. (2018): Current Challenges and Opportunities in Treating Glioblastoma. Pharmacol. Rev., vol. 70, no. 3, pp. 412–445.
[6] Kleihues, P., et al. (2002): The WHO Classification of Tumors of the Nervous System. J. Neuropathol. Exp. Neurol., vol. 61, no. 3, pp. 215–225.
[7] Aldape, K., et al. (2000): Discrepancies in diagnoses of neuroepithelial neoplasms. Cancer, vol. 88, no. 10, pp. 2342–2349.
[8] Brandes, A. A., Tosoni, A., Franceschi, E., Reni, M., Gatta, G., and Vecht, C. (2008): Glioblastoma in adults. Crit. Rev. Oncol. Hematol., vol. 67, no. 2, pp. 139–152.
[9] Andrews, M. G. and Kriegstein, A. R. (2022): Challenges of Organoid Research. Annu. Rev. Neurosci., vol. 45, no. 1, pp. 23–39.
[10] Kırmanoğlu, C. (2025): İn Vitro Modeller: 3 Boyutlu Hücre Kültürü Tekniklerine Yaklaşımlar. In: Akademik perspektiften moleküler biyoloji ve genetik. Yaz Yayınları. Afyonkarahisar, ch. İn Vitro M, pp. 43–58.
[11] Rossi, G., Manfrin, A., and Lutolf, M. P. (2018): Progress and potential in organoid research. Nat. Rev. Genet., vol. 19, no. 11, pp. 671–687.
[12] Eiraku, M., et al. (2008): Self-Organized Formation of Polarized Cortical Tissues from ESCs and Its Active Manipulation by Extrinsic Signals. Cell Stem Cell, vol. 3, no. 5, pp. 519–532.
[13] Kadoshima, T., et al. (2013): Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell–derived neocortex. Proc. Natl. Acad. Sci., vol. 110, no. 50, pp. 20284–20289.
[14] Quadrato, G., et al. (2017): Cell diversity and network dynamics in photosensitive human brain organoids. Nature, vol. 545, no. 7652, pp. 48–53.
[15] Sato, T., et al. (2009): Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature, vol. 459, no. 7244, pp. 262–265.
[16] Gao, D., et al. (2014): Organoid Cultures Derived from Patients with Advanced Prostate Cancer. Cell, vol. 159, no. 1, pp. 176–187.
[17] Hubert, C. G., et al. (2016): A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo. Cancer Res., vol. 76, no. 8, pp. 2465–2477.
[18] Linkous, A., et al. (2019): Modeling Patient-Derived Glioblastoma with Cerebral Organoids. Cell Rep., vol. 26, no. 12, pp. 3203-3211.e5.
[19] Majc, B., et al. (2024): Patient-derived tumor organoids mimic treatment-induced DNA damage response in glioblastoma. iScience, vol. 27, no. 9, p. 110604.
[20] Ishahak, M., et al. (2025): Genetically Engineered Brain Organoids Recapitulate Spatial and Developmental States of Glioblastoma Progression. Adv. Sci., vol. 12, no. 10.
[21] Ou, A., Yung, W. K. A., and Majd, N. (2020): Molecular Mechanisms of Treatment Resistance in Glioblastoma. Int. J. Mol. Sci., vol. 22, no. 1, p. 351.
[22] Ueda, K., et al. (1986): The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem. Biophys. Res. Commun., vol. 141, no. 3, pp. 956–962.
[23] Cole, S. P. C., et al. (1992): Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line. Science, vol. 258, no. 5088, pp. 1650–1654.
[24] Daneman, R. and Prat, A. (2015): The Blood–Brain Barrier. Cold Spring Harb. Perspect. Biol., vol. 7, no. 1, p. a020412.
[25] Ballabh, P., Braun, A., and Nedergaard, M. (2004): The blood–brain barrier: an overview. Neurobiol. Dis., vol. 16, no. 1, pp. 1–13.
[26] Verhaak, R. G. W., et al. (2010): Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, vol. 17, no. 1, pp. 98–110.
[27] Nature Editorial. (2008): Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, vol. 455, no. 7216, pp. 1061–1068.)
[28] Artegiani, B. and H. Clevers. (2018): Use and application of 3D-organoid technology. Hum. Mol. Genet., vol. 27, no. R2, pp. R99–R107.
[29] Broutier, L., et al. (2017): Human primary liver cancer–derived organoid cultures for disease modeling and drug screening. Nat. Med., vol. 23, no. 12, pp. 1424–1435.
[30] Drost, J., et al. (2016): Organoid culture systems for prostate epithelial and cancer tissue. Nat. Protoc., vol. 11, no. 2, pp. 347–358.
[31] Shimokawa, M., et al. (2017): Visualization and targeting of LGR5+ human colon cancer stem cells. Nature, vol. 545, no. 7653, pp. 187–192.
[32] Huang, L., et al. (2015): Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell– and patient-derived tumor organoids. Nat. Med., vol. 21, no. 11, pp. 1364–1371.
[33] Wang, K., et al. (2014): Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat. Genet., vol. 46, no. 6, pp. 573–582.
[34] Sachs, N., et al. (2018): A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell, vol. 172, no. 1–2, pp. 373-386.e10.
[35] Yang, H., Zhang, N., and Liu, Y.-C. (2020): An organoids biobank for recapitulating tumor heterogeneity and personalized medicine. Chinese J. Cancer Res., vol. 32, no. 3, pp. 408–413.
[36] Xu, H., Lyu, M., Yi, W., Zhao, W., Song, Y., and Wu, K. (2018): Organoid technology and applications in cancer research. J. Hematol. Oncol., vol. 11, no. 1, p. 116.
[37] Tuveson, D. and Clevers, H. (2019): Cancer modeling meets human organoid technology. Science, vol. 364, no. 6444, pp. 952–955.
[38] Sandborn, W. J., et al. (2017): Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med., vol. 376, no. 18, pp. 1723–1736.
[39] Barnhoorn, M. C., et al. (2020): Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn’s Disease Perianal Fistulas. J. Crohn’s Colitis, vol. 14, no. 1, pp. 64–70.
[40] Brierley, C. K., et al. (2018): Autologous Haematopoietic Stem Cell Transplantation for Crohn’s Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation. J. Crohn’s Colitis.
[41] Chen, J., et al. (2023): Nestin+ Peyer’s patch resident MSCs enhance healing of inflammatory bowel disease through IL‐22‐mediated intestinal epithelial repair. Cell Prolif., vol. 56, no. 2.)
[42] Xue, J., et al. (2024): A tumorigenicity evaluation platform for cell therapies based on brain organoids. Transl. Neurodegener., vol. 13, no. 1, p. 53.
[43] Batara, D. C. R., Zhou, S., Choi, M.-C., and Kim, S.-H. (2022): Glioblastoma organoid technology: an emerging preclinical models for drug discovery. Organoid, vol. 2, p. e7.
[44] Soto-Gamez, A., Gunawan, J. P., Barazzuol, L., Pringle, S., and Coppes, R. P. (2024): Organoid-based personalized medicine: from tumor outcome prediction to autologous transplantation. Stem Cells, vol. 42, no. 6, pp. 499–508.
[45] Zhou, Z., Cong, L., and Cong, X. (2021): Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank. Front. Oncol., vol.11.
[46] Van de Wetering, M., et al. (2015): Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients. Cell, vol. 161, no. 4, pp. 933–945.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Türk Bilimsel Derlemeler Dergisi
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
